AN2 Therapeutics Inc (ANTX) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Grant from the Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and...

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics...

Form 8-A12B - Registration of securities [Section 12(b)]

Form 8-K - Current report

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics...